In the course of its growth strategy Zur Rose Group agreed to a two-step capital increase by KWE Beteiligungen AG, a subsidiary of the Swiss investment company Corisol Holding AG. After having invested the first tranche of CHF 20 m, Corisol Holding holds 13.3 percent of the equity capital. A second tranche will increase the total investment to up to CHF 44 m. With this investment Corisol strives to achieve a strategic minority interest in Zur Rose Group. The raised capital supports Zur Rose Group to further strengthen its equity basis as well as to finance its growth strategy.

Homburger acted as lead counsel to Zur Rose Group in this transaction. The client is a leading Swiss wholesaler and B2C mail order distributor of drugs and medical products with its well-known brands "Zur Rose" and "DocMorris".

The Homburger team was led by partner Georg Rauber (IP | IT) and comprised Dieter Gericke, David Oser (both partners, Corporate | M&A), Luca Dal Molin and Roman Perrig (both associates, IP | IT), Micha Fankhauser (counsel) and Daniel Häusermann (associate, both Corporate | M&A), Simon Bühler (associate, Financial Services).